For pulmonary arterial hypertension, currently marketed methods of treprostinil administration include intravenous, subcutaneous and inhalation. Oral treprostinil is actively being investigated.

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

In a report released on January 24, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Insmed (INSM – Research Report), with a ...